Market revenue in 2023 | USD 3,156.1 million |
Market revenue in 2030 | USD 5,622.4 million |
Growth rate | 8.6% (CAGR from 2023 to 2030) |
Largest segment | Contract manufacturing |
Fastest growing segment | Contract Development |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Contract Manufacturing, Contract Development |
Key market players worldwide | Eurofins Scientific SE, WuXi Biologics (Cayman) Inc, Catalent Inc, AGC Inc, Siegfried Holding AG, Boehringer Ingelheim, FUJIFILM Holdings Corp, Samsung BioLogics, Rentschler Biopharma SE, Recipharm |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to large molecule drug substance cdmo market will help companies and investors design strategic landscapes.
Contract manufacturing was the largest segment with a revenue share of 67% in 2023. Horizon Databook has segmented the U.S. large molecule drug substance cdmo market based on contract manufacturing, contract development covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. accounts for the largest share in North America market and is projected to grow at a significant rate over the forecast period. Increase in outsourcing by pharmaceutical companies and support of CDMOs in reducing operational & capital expenses are among the key factors responsible for lucrative growth.
Also, rise in R&D spending for biologics development coupled with presence of large number of FDA-approved drugs in the country is driving the market.
The U.S. hosts a large number of biopharmaceutical pipeline in various stages of development. More than 900 biologic molecules are under clinical investigation in the country.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. large molecule drug substance cdmo market , including forecasts for subscribers. This country databook contains high-level insights into U.S. large molecule drug substance cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account